Literature DB >> 19387498

Design of biologically active heparan sulfate and heparin using an enzyme-based approach.

Sherket Peterson1, Amber Frick, Jian Liu.   

Abstract

Covering: up to August 2008. Heparan sulfate (HS) is a highly sulfated polysaccharide that plays essential physiological and pathophysiological roles. Heparin, a special form of HS, is a commonly used anticoagulant drug. The biosynthesis of HS involves numerous enzymes, including sulfotransferases, glycosyl transferases and an epimerase. It is widely believed that unique sulfation patterns is critical for elucidating the function-structure relationship of this important class of biomolecules. The chemical syntheses of such sulfated saccharides, especially molecules larger than an octasaccharide, are extremely difficult. Therefore, employing HS biosynthetic enzymes to synthesize HS that has the desired biological functions offers an attractive alternative. This review presents the recent progress on this approach. In addition, we discuss the mechanism used by HS sulfotransferases to recognize specific sulfated saccharide sequences. 186 References are cited.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19387498     DOI: 10.1039/b803795g

Source DB:  PubMed          Journal:  Nat Prod Rep        ISSN: 0265-0568            Impact factor:   13.423


  30 in total

1.  Directing the biological activities of heparan sulfate oligosaccharides using a chemoenzymatic approach.

Authors:  Yongmei Xu; Zhen Wang; Renpeng Liu; Arlene S Bridges; Xuefei Huang; Jian Liu
Journal:  Glycobiology       Date:  2011-08-11       Impact factor: 4.313

2.  Chemoenzymatic design of heparan sulfate oligosaccharides.

Authors:  Renpeng Liu; Yongmei Xu; Miao Chen; Michel Weïwer; Xianxuan Zhou; Arlene S Bridges; Paul L DeAngelis; Qisheng Zhang; Robert J Linhardt; Jian Liu
Journal:  J Biol Chem       Date:  2010-08-21       Impact factor: 5.157

3.  Chemoenzymatic synthesis of heparin oligosaccharides with both anti-factor Xa and anti-factor IIa activities.

Authors:  Yongmei Xu; Elizabeth H Pempe; Jian Liu
Journal:  J Biol Chem       Date:  2012-07-06       Impact factor: 5.157

4.  Expression of heparan sulfate sulfotransferases in Kluyveromyces lactis and preparation of 3'-phosphoadenosine-5'-phosphosulfate.

Authors:  Xianxuan Zhou; Kasemsiri Chandarajoti; Truong Quang Pham; Renpeng Liu; Jian Liu
Journal:  Glycobiology       Date:  2011-01-11       Impact factor: 4.313

5.  Fibroblast growth factor-based signaling through synthetic heparan sulfate blocks copolymers studied using high cell density three-dimensional cell printing.

Authors:  Eric Sterner; Sayaka Masuko; Guoyun Li; Lingyun Li; Dixy E Green; Nigel J Otto; Yongmei Xu; Paul L DeAngelis; Jian Liu; Jonathan S Dordick; Robert J Linhardt
Journal:  J Biol Chem       Date:  2014-02-22       Impact factor: 5.157

6.  Chemoenzymatic synthesis of homogeneous ultralow molecular weight heparins.

Authors:  Yongmei Xu; Sayaka Masuko; Majde Takieddin; Haoming Xu; Renpeng Liu; Juliana Jing; Shaker A Mousa; Robert J Linhardt; Jian Liu
Journal:  Science       Date:  2011-10-28       Impact factor: 47.728

Review 7.  Synthetic Oligosaccharide Libraries and Microarray Technology: A Powerful Combination for the Success of Current Glycosaminoglycan Interactomics.

Authors:  Vitor H Pomin; Xu Wang
Journal:  ChemMedChem       Date:  2017-12-06       Impact factor: 3.466

Review 8.  Chemoenzymatic synthesis of glycosaminoglycans: re-creating, re-modeling and re-designing nature's longest or most complex carbohydrate chains.

Authors:  Paul L DeAngelis; Jian Liu; Robert J Linhardt
Journal:  Glycobiology       Date:  2013-03-11       Impact factor: 4.313

Review 9.  Recent progress and applications in glycosaminoglycan and heparin research.

Authors:  Tatiana N Laremore; Fuming Zhang; Jonathan S Dordick; Jian Liu; Robert J Linhardt
Journal:  Curr Opin Chem Biol       Date:  2009-09-24       Impact factor: 8.822

Review 10.  The design and synthesis of new synthetic low-molecular-weight heparins.

Authors:  K Chandarajoti; J Liu; R Pawlinski
Journal:  J Thromb Haemost       Date:  2016-04-15       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.